INFI News and Press, Infinity Pharmaceuticals Inc. From 02/09/23

VANCOUVER, BC / ACCESSWIRE / February 9, 2023 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company ") announces that Matt Hudson has been appointed as President and CEO of the Company effective February 1, 2023. Matt's operational experience in Mexico, knowledge of c...

VANCOUVER, BC / ACCESSWIRE / January 30, 2023 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company ") announces that it has signed an agreement granting Prismo Metals Inc. (CSE: PRIZ, OTCQB: PMOMF) ("Prismo") the option to acquire up to a 75% interest in the Hot Brec...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will ...

Infinity Pharma ( NASDAQ: INFI ) is trading ~24% lower after the company missed revenue estimates. Revenue rose 65.1% Y/Y to $0.71M, way below estimates of $8.12M. The company posted Q3 GAAP EPS of -$0.12. Infinity said it continues to expect net loss for 2...

Infinity Pharmaceuticals press release ( NASDAQ: INFI ): Q3 GAAP EPS of -$0.12. Revenue of $0.71M (+65.1% Y/Y). At September 30, 2022, Infinity had total cash and cash equivalents of $47.2 million, compared to $80.7 million at December 31, 2021. FY Outlook: Net...

– MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with goal of announcing a partners...

Infinity Pharmaceuticals ( NASDAQ: INFI ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$0.14 (-16.7% Y/Y) and the consensus Revenue Estimate is $8.12M (+1788.4% Y/Y). Over the last 3 months, E...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial ...

Summary Today, we revisit small oncology concern Infinity Pharmaceuticals for the first time in 2022. The company's primary drug Eganelisib has shown encouraging results as part of combination therapies, but the company is waiting on a collaboration deal to move development forwar...

Shares of micro-cap clinical-stage biotech Infinity Pharmaceuticals ( NASDAQ: INFI ) jumped 24.3% to $0.92 in Wednesday mid-day trading, after it announced data from a two-year analysis of an ongoing study and reported Q2 results. Cambridge, Mass.-based INFI is developin...